Big moves continue!

Regarding Hengrui's successive major moves in recent times: personnel changes, continuous cooperation with local pharmaceutical companies, etc.

01 Confirm personnel changes

On October 14th, Hengrui Medicine confirmed to Cyberjaya that Joseph E.

Hengrui Medicine stated that the appointment of Dr.

Looking at Hengrui's layout in the field of innovative drugs in recent years, it is not difficult to find that internationalization is already one of Hengrui's key development directions

For example, Hengrui sold the foreign rights and interests of PD-1 antibody SHR-1210 with independent intellectual property rights to Incyte of the United States for a down payment of US$25 million and a total price of US$770 million, and then Carrelizumab was carried out again.

On October 10th, Zhang Lianshan, Senior Deputy General Manager and President of Global R&D of Hengrui Pharmaceuticals, stated at the 2021 Biopharmaceutical Process Development Summit BPD that China’s innovative drugs are an inevitable choice to “go global”

Zhang Lianshan believes that the huge overseas pharmaceutical market space, favorable policies for domestic and foreign drug supervision, the improvement of domestic pharmaceutical companies' R&D strength, and the assistance of capital markets and CXO are all reasons why domestic innovative drugs are going out

02will still actively cooperate

In addition to personnel changes, the recent successive external cooperation of Hengrui has also attracted the attention of the industry

In September alone, Hengrui sold more than hundreds of millions of dollars

First announced an agreement with Beijing-day Biotechnology Co.

Then he announced the start healing Biotechnology (Shanghai) Co.

Back in August, Hengrui announced the signing of a strategic cooperation agreement with Dalian Wanchun Bulin Pharmaceutical Co.

The industry has different views on Hengrui's short-term cooperation

Hengrui pointed out to Cyberlan that Hengrui has been paying close attention to the progress of external innovations and actively introducing high-quality products, such as two drugs for dry eye treatment imported from Novaliq in Germany, and treatments imported from Mycovia in the United States.

Will it cooperate with other pharmaceutical companies in the future? How did Hengrui evaluate a company's innovation capability before deciding to cooperate?

Hengrui said, “As long as there is no layout within the company, or a project with a layout but not good enough or too slow in progress, and varieties and projects that conform to the company’s development strategy, Hengrui is willing to cooperate with industry-leading companies

03 How to innovate in the future

The 2021 semi-annual report shows that during the reporting period, Hengrui invested 2.

Hengrui believes that under the current fierce competition for innovative drugs, "first-in-class" drugs are the goals pursued by major companies
.
China's original research drugs must be recognized worldwide, and it is necessary to strengthen the development of new targets and cutting-edge targets, and make differentiated products to be competitive in the market
.
The emergence and iteration of new technologies, such as artificial intelligence, gene editing, etc.
, all contribute to target discovery and the development of "first-in-class" drugs
.

Facing fierce external competition, Hengrui has deployed cutting-edge targets in all major therapeutic areas, including tumor immunity, autoimmune diseases, anti-infection, analgesia, etc.
, based on multiple internally established technology platforms with independent intellectual property rights , Has developed a number of potential molecules, and currently some molecules have entered the stage of clinical development
.

Regarding the next development in the field of innovative drugs, Hengrui revealed to Cyberlan that it will further strengthen the construction of a new platform and develop molecules with differentiated characteristics based on the platform
.
At the same time, it is actively deploying new molecular forms, such as gene therapy, mRNA, nuclear medicine, etc.
, with the help of Hengrui's R&D team advantages built over the years, to promote innovative research and development as soon as possible
.

Hengrui believes that in the process of innovation and development, companies must do three things:

First, we must be pragmatic
.
It is impossible to build an independent and controllable industrial system in one step.
In the field of basic research and original innovation, there is a big gap between us and the developed countries, and we must face this point squarely
.
Therefore, for most companies, following is a more realistic innovation strategy.
In this process, they can do better than others
.

Second, be focused
.
At the end of the last century, Hengrui determined its development strategy for innovation and transformation
.
From the initial attempts through industry-university-research, cooperation with foreign scientific research institutions, etc.
, to later spending huge sums of money to introduce talents and build its own innovation system, these have also created conditions for innovative drugs to enter the global market
.

Third, we must be willing to invest
.
The research and development of original drugs has high risk, large investment, and long cycle.
Researchers have screened 10,000 compounds, and only less than 10 can enter the clinic.
In the end, only one or two may be approved for marketing.
This process will take more than ten years and a few investment One billion yuan
.
Taking the path of innovative drugs is a huge test for the strength, ability and determination of an enterprise
.